Ansa Biotechnologies, Inc.

Ansa Biotechnologies, Inc.

is a biotechnology company based in Emeryville, California, focused on developing and commercializing next-generation enzymatic DNA synthesis technology. Founded in 2018 as a spin-out from the Joint BioEnergy Institute and UC Berkeley, Ansa aims to transform the DNA manufacturing industry by introducing a faster and more accurate enzyme-based approach to DNA synthesis. The company has raised approximately $82.7 million in funding and employs around 70–77 people. Ansa operates primarily as a B2B service provider, offering made-to-order synthetic DNA. Their services include the synthesis of gene-length DNA molecules directly from customer-submitted sequences, with a transparent per-base-pair pricing model and an on-time delivery guarantee. Key products include the 50 kilobase clonal DNA product, which is the longest sequence-perfect synthetic DNA available, and a robust enzymatic DNA synthesis platform. Ansa serves various sectors, including pharmaceuticals, gene therapy, synthetic biology, and agricultural biotechnology, providing essential DNA building blocks for research and development.